NCT07192341 Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
| NCT ID | NCT07192341 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kafrelsheikh University |
| Condition | Sacubitril/Valsartan |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2025-09-27 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2025-09-27 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old. * Both sexes. * Patients with a history of prosthetic heart valves. * Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV. Exclusion Criteria: * Hemodynamic instability. * Use of a circulatory auxiliary circulation device. * Severe hepatic \[alanine aminotransferase (ALT) \>120 U/L\] and renal insufficiency \[estimated glomerular filtration rate (eGFR) \<30 mL/min\]. * Blood pressure \<100/60 mmHg. * Serum potassium \>5.3 mmol/L. * Severe pulmonary hypertension. * Malignant arrhythmia. * Malignant tumor. * Known history of hereditary or primary angioedema. * Serious adverse drug reactions or serious complications over the course of treatment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07192341 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sacubitril/Valsartan. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07192341 currently recruiting?
Yes, NCT07192341 is actively recruiting participants. Contact the research team at drhammad879@gmail.com for enrollment information.
Where is the NCT07192341 trial being conducted?
This trial is being conducted at Kafr ash Shaykh, Egypt.
Who is sponsoring the NCT07192341 clinical trial?
NCT07192341 is sponsored by Kafrelsheikh University. The trial plans to enroll 220 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.